T1	Participants 148 187	patients with relapsed multiple myeloma
T2	Participants 238 368	59 patients with relapsed multiple myeloma were randomised to receive or not to receive subsequent alpha-2b interferon maintenance
T3	Participants 370 583	13 patients (22%) [8 of 31 (26%) controls, 5 of 28 (18%) in the interferon arm] received single hemi-body irradiation alone due to progressive disease and/or persistent cytopoenias following the initial procedure.
T4	Participants 671 682	23 patients
T5	Participants 1188 1219	control and interferon patients
